Ixogen has identified the manufacturing process and compiled a roadmap of activities that need to be undertaken for an efficient, robust, and commercially-viable approach to virus production. 

Ixogen is in discussions with major Contract Manufacturing Organisations (CMOs) to assess their Good Manufacturing Practices (GMP) production capacity, quality and cost.  

Ixogen has shortlisted four CMOs for the development and manufacture of Ixovex-1 for use in clinical testing and scaled commercial production following regulatory approval.